Skip to Main content Skip to Navigation
Journal articles

IL-33-expanded human Vγ9Vδ2 T cells have anti-lymphoma effect in a mouse tumor model

Abstract : From several years, the anticancer effects of Vγ9 T lymphocytes make these cells good candidates for cancer immunotherapies. However, the proved efficacy of γδ Τ cell-based cancer immunotherapies in some clinical trials was minimized due to the inherent toxicity of IL-2, which is essential for the combination therapy with Phosphoantigen (PAg). Recently, we showed that IL-33, a γ chain receptor-independent cytokine, was able to induce the in vitro proliferation of PAg-activated Vγ9 T cells, which were fully functional expressing IFN-γ and TNF-α and showing in vitro anti-tumor cytotoxicity. We proposed IL-33 as an alternative to IL-2 for Vγ9 T cell-based cancer immunotherapies, and have therefore evaluated the efficacy of this cytokine in preclinical investigations. This study shows that human Vγ9 T cells are able to proliferate in a mouse model with the combination of PAg and rhIL-33, and that IL-33-expanded Vγ9 T cells can prevent tumor growth in a mouse lymphoma model.
Document type :
Journal articles
Complete list of metadata
Contributor : Mary Poupot Connect in order to contact the contributor
Submitted on : Monday, February 10, 2020 - 9:43:09 AM
Last modification on : Wednesday, November 3, 2021 - 5:37:56 AM




Caroline Duault, Delphine Bétous, Christine Bezombes, Stéphane Roga, Corinne Cayrol, et al.. IL-33-expanded human Vγ9Vδ2 T cells have anti-lymphoma effect in a mouse tumor model. European Journal of Immunology, Wiley-VCH Verlag, 2017, 47 (12), pp.2137-2141. ⟨10.1002/eji.201747093⟩. ⟨inserm-02472191⟩



Record views